ABSENT CD33 IN AML PATIENTS: FROM DIAGNOSIS TO FOLLOW-UPS

ABSENT CD33 IN AML PATIENTS: FROM DIAGNOSIS TO FOLLOW-UPS

Background: Despite recent advances and development of new therapeutic targets and personalized medicine, acute myeloid leukemia (AML) treatment remains defiant. Identification of residual leukemic cells (measurable residual disease -MRD) by Multiparametric Flow Cytometry has been a fast and effecti...

Full description

Bibliographic Details
Main Authors: Leticia O. Marani, Amanda Costa, Fernanda B. Silva, Maria Izabel A. Madeira, Priscila S. Scheucher, Josiane L.S. Schiavinato, Ana Silvia G. Lima, Katia B.B. Pagnano, Bruno K. Duarte, Sylvie Freeman, Eduardo M. Rego, Fabiola Traina, Lorena L. Figueiredo-Pontes
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:Hematology, Transfusion and Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137923000482

Internet

http://www.sciencedirect.com/science/article/pii/S2531137923000482

Similar Items